Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience

Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience

Abstract Background A fixed 8-cycle oxaliplatin and capecitabine (XELOX) regimen has been the standard adjuvant therapy for patients with stage III colon cancer. However, completing the full-cycle of oxaliplatin is often associated with severe neurotoxicity. To spare patients from the toxic effects,...

Full description

Bibliographic Details
Main Authors: Jianhong Peng, Weihao Li, Rongxin Zhang, Junzhong Lin, Jinghua Tang, Yongshan Wen, Zhenhai Lu, Xiaojun Wu, Zhizhong Pan
Format: Article
Language:English
Published: Wiley 2019-10-01
Series:Cancer Communications
Subjects:
Colon cancer
Adjuvant chemotherapy
Oxaliplatin
Capecitabine
XELOX
Efficacy
Online Access:http://link.springer.com/article/10.1186/s40880-019-0400-x

Internet

http://link.springer.com/article/10.1186/s40880-019-0400-x

Similar Items